Cargando…

Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer

Approximately 20–30% of endometrial carcinomas (EC) are characterized by mismatch repair (MMR) deficiency (dMMR) or microsatellite instability (MSI), and their testing has become part of the routine diagnosis. The aim of this study was to establish and compare the MMR status using various approaches...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendiola, Marta, Heredia-Soto, Victoria, Ruz-Caracuel, Ignacio, Baillo, Amparo, Ramon-Patino, Jorge Luis, Escudero, Francisco Javier, Miguel, Maria, Pelaez-Garcia, Alberto, Hernandez, Alicia, Feliu, Jaime, Hardisson, David, Redondo, Andres
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572657/ https://www.ncbi.nlm.nih.gov/pubmed/37833916 http://dx.doi.org/10.3390/ijms241914468

Ejemplares similares

Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2019)

Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2021)

Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling
por: López-Janeiro, Álvaro, et al.
Publicado: (2021)

Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
por: Jungen, Samuel H., et al.
Publicado: (2023)

In-depth quantitative proteomics analysis revealed C1GALT1 depletion in ECC-1 cells mimics an aggressive endometrial cancer phenotype observed in cancer patients with low C1GALT1 expression
por: Montero-Calle, Ana, et al.
Publicado: (2023)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
por: Heredia-Soto, Victoria, et al.
Publicado: (2022)

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease
por: Heredia-Soto, Victoria, et al.
Publicado: (2018)

The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
por: López‐Janeiro, Álvaro, et al.
Publicado: (2022)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer
por: Masuda, Kenta, et al.
Publicado: (2011)

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
por: Escudero, Javier, et al.
Publicado: (2021)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance
por: Fernández, Lara P., et al.
Publicado: (2018)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands
por: Walker, Romy, et al.
Publicado: (2023)

Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
por: Heredia-Soto, Victoria, et al.
Publicado: (2021)

Clinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia
por: Han, Su Jin, et al.
Publicado: (2015)

Targeted sequencing of genes associated with the mismatch repair pathway in patients with endometrial cancer
por: Singh, Ashish Kumar, et al.
Publicado: (2020)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort
por: Lawrence, Jessica, et al.
Publicado: (2021)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status
por: de Freitas, Daniela, et al.
Publicado: (2023)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

100 problemas resueltos de estadística multivariante : (implementados en Matlab)
por: Baillo Moreno, Amparo
Publicado: (2007)

DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers
por: Kato, Masafumi, et al.
Publicado: (2015)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies
por: Ryan, Neil A. J., et al.
Publicado: (2021)

Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma
por: Loukovaara, Mikko, et al.
Publicado: (2021)

Lost opportunities for mismatch repair (MMR) screening among minority women with endometrial cancer
por: Huang, Marilyn, et al.
Publicado: (2021)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review
por: Favier, Amelia, et al.
Publicado: (2022)

Screening of Lynch syndrome in endometrial cancer in Iranian population with mismatch repair protein by immunohistochemistry
por: Noei Teymoordash, Somayyeh, et al.
Publicado: (2022)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer
por: Polychronidou, Genovefa, et al.
Publicado: (2018)

MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas
por: Kaneko, Enami, et al.
Publicado: (2021)

The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma
por: Liu, Xiaojuan, et al.
Publicado: (2022)

Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis
por: Jumaah, Alaa Salah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kuk7uoqpu9bf6sj6rnb2qshdjt